Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625725 · ClinicalTrials.gov registry record · Phase 3
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,197
- Enrollment target
NCT04625725 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 5,197 participants.
The verdict
NCT04625725, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,197 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
Interventions
- DRUG Placebo
- DRUG AZD7442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,197 participants |
| Start Date | 2020-11-21 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04625725
The ClinicalTrials.gov registry entry for NCT04625725 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04625725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04625725 about?
NCT04625725 is a clinical study titled "Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.". This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
What is the current status of trial NCT04625725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,197 participants. The study started on 2020-11-21. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT04625725?
The interventions under investigation include: Placebo (DRUG), AZD7442 (DRUG).
Who is sponsoring clinical trial NCT04625725?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.